来自线粒体的囊泡:对于瘤治疗来说,这是一个有前途和潜在的目标
Xueqiang Peng1,2,3, Yu Gao1,3, Jiaxing Liu1,3
1Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, China.
Clinical and translational medicine
|May 13, 2025
概括
线粒体衍生囊泡 (MDVs) 是早期细胞防御和线粒体质量控制的关键. 这些囊泡还通过帮助细胞间通信和促进癌细胞存活来影响瘤的进展.
科学领域:
- 细胞生物学 细胞生物学
- 线粒体生物学 线粒体生物学
- 癌症生物学 癌症生物学
背景情况:
- 线粒体对于细胞能量生产至关重要;损伤可能导致功能障碍和死亡.
- 线粒体衍生囊泡 (MDVs) 参与早期细胞防御线粒体损伤.
- 通过去除损坏的组件,MDVs在维护线粒体质量控制 (MQC) 中发挥作用.
研究的目的:
- 研究MDVs在细胞防御和线粒体质量控制中的作用.
- 探索MDVs对瘤进展和细胞间通信的影响.
- 突出MDV作为癌症治疗中的治疗点的潜力.
主要方法:
- 对线粒体损伤的细胞反应的分析.
- 在压力条件下的MDV生物发生和货物的调查.
- 在瘤微环境中检查MDV介导的细胞间通信.
主要成果:
- MDVs对于细胞早期应激反应至关重要,在线粒细胞衰变之前.
- MDV选择性地包装和运输受损的线粒体蛋白质,减轻细胞损伤.
- 通过促进细胞间通信和促进癌细胞存活和扩散,MDVs有助于瘤的进展.
结论:
- MDV对于维护线粒体健康和细胞平衡至关重要.
- MDVs在细胞防御和促进瘤进展方面发挥着双重作用.
- 针对MDVs为新型癌症疗法提供了一个有希望的途径.
相关概念视频
Tumor Immunotherapy
432
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
432
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Intralumenal Vesicles and Multivesicular Bodies
3.3K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.3K
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Translocation of Proteins into the Mitochondria
3.0K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
3.0K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


